Page last updated: 2024-08-26

wr 1065 and Cancer of Ovary

wr 1065 has been researched along with Cancer of Ovary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aickin, M; Alberts, DS; Barrett, A; Capizzi, RL; Conlon, J; Krutzsch, M; Speicher, LA; Wymer, J	1

Other Studies

1 other study(ies) available for wr 1065 and Cancer of Ovary

Article	Year
WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 4 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mercaptoethylamines; Ovarian Neoplasms; Tumor Cells, Cultured	1996

Article

Year

WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells.

European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 4

Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mercaptoethylamines; Ovarian Neoplasms; Tumor Cells, Cultured

1996